Histogenics (HSGX) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Histogenics (HSGX) Misses Q2 EPS by 1c

Histogenics Corporation Announces Second Quarter 2016 Financial and Operating Results

August 11, 2016 6:30 AM EDT

- NeoCart® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -

WALTHAM, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2016. 

We are very pleased with the... More